Zealand Pharma A/S (OCSE:ZEAL) Deferred Tax : kr0.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Zealand Pharma A/S Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Zealand Pharma A/S's change in deferred tax for the three months ended in Dec. 2023 was kr0.0 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Dec. 2023 was kr0.0 Mil.

Zealand Pharma A/S Deferred Tax Historical Data

The historical data trend for Zealand Pharma A/S's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S Deferred Tax Chart

Zealand Pharma A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Deferred Tax

Get a 7-Day Free Trial

-5.39

9.87

-1.19

9.89

-5.13

Zealand Pharma A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Deferred Tax	Get a 7-Day Free Trial															-	-	-	-	-

Zealand Pharma A/S Deferred Tax Calculation

Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.0 Mil.

Zealand Pharma A/S Deferred Tax Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Zealand Pharma A/S (OCSE:ZEAL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OCSE:ZEAL) » Definitions » Deferred Tax

Comparable Companies

Traded in Other Exchanges

ZLDPF:USA ZEALc:UK 0NZU:UK 22Z:Germany

Address

Sydmarken 11, Soborg, DNK, DK-2860

Website

https://www.zealandpharma.com

Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.